Sansum Diabetes Research Institute logo

Sansum Diabetes Research Institute Unveils 2022 Annual Report

Inspiring Hope, Advancing Research

Sansum Diabetes Research Institute (SDRI), a global nonprofit dedicated to improving the lives of individuals impacted by diabetes through research, education, and clinical care, is delighted to announce the release of its highly anticipated Annual Report for the fiscal year 2022. The Annual Report showcases SDRI’s unwavering commitment to its mission and the transformative power it holds. It provides a comprehensive overview of SDRI’s activities, initiatives, and accomplishments throughout the year, highlighting the significant progress made in advancing its core objectives.

“Releasing our 2022 Annual Report is a significant milestone for SDRI,” said Ellen Goodstein, SDRI’s Executive Director. “It provides an opportunity for us to reflect on our achievements, celebrate the progress we have made, and acknowledge the ongoing challenges faced by the diabetes community. The report showcases our commitment to making a positive impact for individuals impacted by diabetes and driving change in diabetes research.”

Key highlights from the report include inspiring stories of individuals whose lives have been positively impacted by SDRI’s programs and services, groundbreaking research conducted in 2022, invaluable contributions of partners, donors, and volunteers who have played a pivotal role in supporting SDRI’s profound work, and a transparent breakdown of SDRI’s financials.

 SDRI’s innovative research in 2022 includes a landmark study that evaluated the efficacy of the Dexcom G7 Continuous Glucose Monitor (CGM) in pregnancy, resulting in the FDA approval of the CGM for use during pregnancy. The Institute also conducted pivotal trials for the Dexcom G7 CGM for use in patients 2 years and older and controlled trials evaluating a culturally tailored plant-forward diet and lifestyle therapy program for the underserved Latino population.

SDRI’s 2022 Annual Report also highlights the strong collaborations and partnerships with prestigious institutions, including the establishment of a 16-member Scientific Advisory Board comprised of global experts in diabetes research.

The report showcases the organization’s outstanding achievements, impactful programs, and continued dedication to making a difference in the lives of individuals and communities impacted by diabetes. In 2022, SDRI engaged 1,779 individuals in clinical research, conducted 26 clinical research trials, provided care for 105 women living with diabetes during pregnancy, and published 26 articles in highly respected medical journals. SDRI’s life-saving work would not be possible without the generosity and dedication of its incredible donors, supporters, and collaborators.